Zur Kurzanzeige

dc.contributor.authorBlanco, Gonzalo
dc.contributor.authorPuiggros, Anna
dc.contributor.authorBaliakas, Panagiotis
dc.contributor.authorAthanasiadou, Anastasia
dc.contributor.authorGarcía-Malo, MªDolores
dc.contributor.authorCollado, Rosa
dc.contributor.authorXochelli, Aliki
dc.contributor.authorRodríguez-Rivera, María
dc.contributor.authorOrtega, Margarita
dc.contributor.authorCalasanz, Mª José
dc.contributor.authorLuño, Elisa
dc.contributor.authorVargas, MªTeresa
dc.contributor.authorGrau, Javier
dc.contributor.authorMartínez-Laperche, Carolina
dc.contributor.authorValiente, Alberto
dc.contributor.authorCervera, José
dc.contributor.authorAnagnostopoulos, Achilles
dc.contributor.authorGimeno, Eva
dc.contributor.authorAbella, Eugènia
dc.contributor.authorStalika, Evangelia
dc.contributor.authorHernández Rivas, Jesús María 
dc.contributor.authorOrtuño, Francisco José
dc.contributor.authorRobles, Diego
dc.contributor.authorFerrer, Ana
dc.contributor.authorIvars, David
dc.contributor.authorGonzález, Marcos
dc.contributor.authorBosch, Francesc
dc.contributor.authorAbrisqueta, Pau
dc.contributor.authorStamatopoulos, Kostas
dc.contributor.authorEspinet, Blanca
dc.date.accessioned2020-01-30T11:53:12Z
dc.date.available2020-01-30T11:53:12Z
dc.date.issued2016
dc.identifier.citationBlanco, G., Puiggros, a., et al (2016). Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget, vol. 7 (49), pp: 80916-80924. https://doi.org/10.18632/oncotarget.13106es_ES
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10366/140736
dc.description.abstract[EN] Patients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p−) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p− and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p− (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCLLes_ES
dc.subjectTP53 aberrationses_ES
dc.subjectChromosome 8 abnormalitieses_ES
dc.subjectComplex karyotypees_ES
dc.subjectPrognosises_ES
dc.subject.meshLeukemia*
dc.titleKaryotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with <i>TP53</i> aberrationses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publishversionhttps://doi.org/10.18632/oncotarget.13106
dc.identifier.doi10.18632/oncotarget.13106
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.essn1949-2553
dc.journal.titleOncotargetes_ES
dc.volume.number7es_ES
dc.issue.number49es_ES
dc.page.initial80916es_ES
dc.page.final80924es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsleucemia*


Dateien zu dieser Ressource

Thumbnail

Das Dokument erscheint in:

Zur Kurzanzeige

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Solange nicht anders angezeigt, wird die Lizenz wie folgt beschrieben: Attribution-NonCommercial-NoDerivatives 4.0 Internacional